NUTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NUTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nutex Health Inc NUTX
Nutex Health NUTX -1.14% 75 ROCE % is 60.12% as of Jun. 2026. GuruFocus rates NUTX with a GF Score™ of 75/100 and a GF Value™ of $82.60 (Significantly Overvalued). The stock has 6 warning signs investors should review.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nutex Health's annualized ROCE % for the quarter that ended in Jun. 2026 was 60.12%.
Nutex Health (NAS:NUTX) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
The historical data trend for Nutex Health's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Nutex Health Annual Data | ||||||||||||||||
| Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||
| ROCE % | Get a 7-Day Free Trial | 55.42 | -110.97 | -8.98 | 30.86 | 42.32 | ||||||||||
| Nutex Health Quarterly Data | ||||||||||||||||||||
| Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | Jun26 | |
| ROCE % | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
19.11 | 72.63 | 16.04 | 42.38 | 60.12 | ||
Nutex Health's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:
| ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
| (A: Dec. 2025 ) | (A: Dec. 2024 ) | (A: Dec. 2025 ) | |||||
| = | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
| (A: Dec. 2025 ) | (A: Dec. 2024 ) | (A: Dec. 2025 ) | |||||
| = | 267.007 | / | ( ( (655.32 - 154.225) | + | (918.525 - 157.911) ) | / 2 ) | |
| = | 267.007 | / | ( (501.095 | + | 760.614) | / 2 ) | |
| = | 267.007 | / | 630.8545 | ||||
| = | 42.32 % |
Nutex Health's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:
| ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
| (Q: Jun. 2026 ) | (Q: Mar. 2026 ) | (Q: Jun. 2026 ) | |||||
| = | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
| (Q: Jun. 2026 ) | (Q: Mar. 2026 ) | (Q: Jun. 2026 ) | |||||
| = | 487.024 | / | ( ( (957.318 - 184.436) | + | (964.629 - 117.22) ) | / 2 ) | |
| = | 487.024 | / | ( ( 772.882 | + | 847.409 ) | / 2 ) | |
| = | 487.024 | / | 810.1455 | ||||
| = | 60.12 % |
(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Based on GuruFocus' analysis, Nutex Health stock appears to be overvalued. The current stock price of $191.69 is trading 132.1% above its estimated GF Value™ of $82.60. GuruFocus considers Nutex Health to be Significantly Overvalued.
Key valuation signals for NUTX:
No single metric tells the full story. See the NUTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.